Bloomberg Podcasts
@bloombergpodcasts·503K subscribers·32.4K videos
Netflix Upgraded; Neurocrine to Buy Soleno Therapeutics | Stock Movers
Posted
April 6, 2026
Views
334
Likes
5
Comments
1
Engagement
April 6, 2026
334
5
1
1.80%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
See what was published immediately before and after this episode.
3:43Now PlayingOn this episode of Stock Movers with Alexis Christoforous:
- Gulf Funds Agree to Back Paramount's $81 Billion Takeover of Warner
- Netflix (NFLX) shares are up after Goldman Sachs upgraded the streaming-video company to buy from neutral.
- Neurocrine Biosciences agreed to buy Soleno Therapeutics for $2.9 billion to expand in rare genetic disorders. The biotechnology company will pay $53 per share for Soleno, a 34% premium to its closing share price Thursday, using cash on hand and some pre-payable debt. Both company boards have approved the transaction, which is expected to close within 90 days.
--------
Watch Bloomberg Radio LIVE on YouTube
Weekdays 7am-6pm ET
Follow us on X
Subscribe to our Podcasts:
Bloomberg Daybreak
Bloomberg Surveillance
Bloomberg Intelligence
Balance of Power
Bloomberg Businessweek
Listen on Apple CarPlay and Android Auto with the Bloomberg Business app:
Apple CarPlay
Android Auto
Visit our YouTube channels:
Bloomberg Podcasts
Bloomberg Television
Bloomberg Originals
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
